医学
抗体-药物偶联物
美罗华
耐受性
苯达莫司汀
肿瘤科
内科学
弥漫性大B细胞淋巴瘤
临床试验
耐火材料(行星科学)
临床研究阶段
淋巴瘤
药品
布仑妥昔单抗维多汀
抗体
单克隆抗体
不利影响
药理学
免疫学
霍奇金淋巴瘤
物理
天体生物学
作者
Vincent Camus,Hervé Tilly
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-01-01
卷期号:17 (2): 127-135
被引量:6
标识
DOI:10.2217/fon-2020-0675
摘要
Refractory/relapsed diffuse large B-cell lymphoma remains a major unmet medical need with poor outcome, especially for patients considered ineligible for stem cell transplant. Polatuzumab vedotin (PV) is a first-in-class anti-CD79b antibody–drug conjugate that contains the microtubule inhibitor monomethyl auristatin E. The development of PV is currently very active. This drug was US FDA approved in 2019 in combination with bendamustine and rituximab for the treatment of refractory/relapsed diffuse large B-cell lymphoma in third line and more, after demonstrating relevant efficacy and acceptable safety in a pivotal randomized Phase II trial. This review summarizes the features of this new drug with the primary focus on the clinical work supporting efficacy, relevance and tolerability of PV.
科研通智能强力驱动
Strongly Powered by AbleSci AI